We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

LITE:NASDAQLumentum Holdings Inc. Analysis

Data as of 2026-04-15 - not real-time

$852.79

Latest Price

8/10Risk

Risk Level: High

Executive Summary

Lumentum Holdings (LITE) is riding a wave of AI‑driven demand, with revenue surging 65% YoY and the company reporting that its products are sold out through 2027. Technically, the stock sits above its 20‑day SMA (≈ $774) and 50‑day SMA (≈ $678) and the MACD line sits bullish at +$7.8 above its signal, while the RSI of 59 indicates room for upside without being overbought. However, valuation metrics are extreme: a trailing P/E of 250 versus an industry average of 35, a price‑to‑book of 72, and a DCF‑derived fair value of just $59, implying the market is pricing in a massive premium. The beta of 2.5 and 30‑day volatility of 118% signal high price sensitivity, and the decreasing volume trend adds a liquidity caution. Balance‑sheet stress is evident with a debt‑to‑equity of 392 and negative free cash flow, while operating margins remain modest at ~10%. Recent news of sold‑out inventory through 2027 and a planned U.S. manufacturing expansion reinforce the growth narrative, but the extreme overvaluation and financial leverage temper enthusiasm.
Investors should weigh the short‑term bullish technical setup and AI tailwinds against the long‑term risks of valuation compression and debt load. Until the market price aligns closer to fundamentals, a cautious stance—favoring holds or selective exposure—may be prudent.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 7/10

Key Factors

  • Bullish MACD and price above short‑term SMAs
  • Strong AI‑driven demand and sold‑out inventory
  • Extreme valuation premium relative to DCF fair value

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • Sustained revenue growth and expansion plans
  • High beta and volatility suggesting price swings
  • Elevated debt levels and negative free cash flow

Long Term

> 3 years
Cautious
Model confidence: 8/10

Key Factors

  • Severe overvaluation (P/E 250×, P/B 72×)
  • Financial leverage (debt‑to‑equity > 390)
  • Potential valuation correction as market re‑prices growth

Key Metrics & Analysis

Financial Health

Revenue Growth65.50%
Profit Margin11.95%
P/E Ratio250.1
ROE29.28%
ROA0.29%
Debt/Equity392.48
P/B Ratio71.9
Op. Cash Flow$247.0M
Free Cash Flow$-21325000
Industry P/E35.2

Technical Analysis

TrendBullish
RSI59.6
Support$573.73
Resistance$960.00
MA 20$773.85
MA 50$677.89
MA 200$328.55
MACDBullish
VolumeDecreasing
Fear & Greed Index88.64

Valuation

Fair Value$59.49
Target Price$773.35
Upside/Downside-9.32%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta2.49
Volatility118.15%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.